Calcium Pyrophosphate Dihydrate (CPPD) Crystal Deposition Disease

  • Ann K. Rosenthal
  • Robert A. Terkeltaub


Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease is a clinically heterogeneous disorder that is characterized by the presence of intraarticu-lar CPPD crystals. CPPD crystals deposit primarily in cartilage but can traffic within the joint space. CPPD crystals form in the normally unmineralized peri-cellular matrix of articular hyaline and fibrocartilage. The most common sites of involvement are the knee meniscus, the triangular fibrocartilage of the wrist, and the glenohumeral joint. Asymptomatic disease is common in these sites as well as in others (e.g., the symphy-sis pubis). Pathologic cartilage calcification is promoted by changes in inorganic pyrophosphate (PPi) metabolism, extracellular matrix, and chondrocyte differentiation. CPPD deposition disease has a close and complex relationship with osteoarthritis. CPPD most commonly afflicts the elderly but can occur in younger patients who have a familial variant of the condition or who are afflicted with any of several metabolic diseases that predispose to CPPD deposition. No specific evidence-based therapies for CPPD exist. However, the inflammation promoted by CPPD crystal deposition can be managed successfully in most patients through strategies typically employed for the treatment and prophylaxis of gout.


Synovial Fluid Polymyalgia Rheumatica Deposition Disease CPPD Crystal Calcium Pyrophosphate Dihydrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Alloway J, Moriarty M, Hoogland Y, et al Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis J Rheumatol. 1993;20:111–3PubMedGoogle Scholar
  2. Chollet-Janin A, Finckh A, Dudler J, et al Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007;56:688–92PubMedCrossRefGoogle Scholar
  3. Dieppe P, Crocker P, Corke C, et al Synovial fluid crystals. Q J Med. 1979;48:533–55PubMedGoogle Scholar
  4. Doan TH, Chevalier X, Leparc JM, et al Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al Arthritis Rheum. 2008;58:2210–1PubMedCrossRefGoogle Scholar
  5. Ellman MH, Levin B. Chondrocalcinosis in elderly persons. Arthritis Rheum. 1975;18:43–7PubMedCrossRefGoogle Scholar
  6. Fisseler-Eckhoff A, Muller KM. Arthroscopy and chondrocalcinosis. Arthroscopy 1992;8:98–104PubMedCrossRefGoogle Scholar
  7. Galvez J, Saiz E, Linares L, et al Delayed examination of synovial fluid by ordinary and polarized light microscopy to detect and identify crystals. Ann Rheum Dis. 2002;61:444–7PubMedCrossRefGoogle Scholar
  8. Gerster J, Varisco P, Kern J, et al CPPD crystal deposition disease in patients with rheumatoid arthritis. Clin Rheumatol. 2006;25:468–9PubMedCrossRefGoogle Scholar
  9. Gordon C, Swan A, Dieppe P. Detection of crystals in synovial fluid by light microscopy: sensitivity and reliability. Ann Rheum Dis. 1989;48:737–42PubMedCrossRefGoogle Scholar
  10. Goto S, Umehara J, Aizawa T, et al Crowned dens syndrome. J Bone Joint Surg Am. 2007;89:2732–6PubMedCrossRefGoogle Scholar
  11. Hasselbacher P. Variation in synovial fluid analysis by hospital laboratories. Arthritis Rheum. 1987;30:637–42PubMedCrossRefGoogle Scholar
  12. Hearn P, Russell R, Elliott J, et al Formation products of calcium pyro-phosphate crystals in vitro and the effect of iron salts. Clin Sci. 1978;54:29PGoogle Scholar
  13. Job-Deslandre C, Menkes CJ, Guinot M, et al Does hypothyroidism increase the prevalence of chondrocalcinosis? Br J Rheumatol. 1993;32:177–9CrossRefGoogle Scholar
  14. Komatireddy GR, Ellman MH, Brown NL. Lack of association between hypothyroidism and chondrocalcinosis. J Rheumatol. 1989;16:807–8PubMedGoogle Scholar
  15. Martinez-Sanchis A, Pascual E. Intracellular and extracellular CPPD crystals are a regular feature in synovial fluid from uninflamed joints of patients with CPPD related arthropathy. Ann Rheum Dis. 2005; 64:1769–72PubMedCrossRefGoogle Scholar
  16. Masuda I, Ishikawa K. Clinical features of pseudogout attack: a survey of 50 cases. Clin Orth Rel Res. 1987;229:173–81Google Scholar
  17. McCarty DJ. Diagnostic mimicry in arthritis: patterns of joint involvement associated with calcium pyrophosphate dihydrate crystal deposits. Ann Rheum Dis. 1975;25:804–9Google Scholar
  18. Mitrovic D, Stankovic A, Iriarte-Borda O, et al The prevalence of chon-drocalcinosis in the human knee joint. An autopsy survey. J Rheumatol. 1988;15:633–41Google Scholar
  19. Neogi T, Nevitt M, Niu J, et al Lack of association between chondrocal-cinosis and increased risk of cartilage loss in knees with osteoarthri-tis: results of two prospective longitudinal magnetic resonance imaging studies. Arthritis Rheum. 2006;54:1822–8PubMedCrossRefGoogle Scholar
  20. O'Duffy J. Clinical studies of acute pseudogout attacks. Comments on prevalence, predisposition and treatment. Arthritis Rheum. 1976;19 (Suppl):349–52PubMedCrossRefGoogle Scholar
  21. Roane D, Harris M, Carpenter M, et al Prospective use of intramuscular triamcinolone in pseudogout. J Rheumatol. 1997;24:1168–70PubMedGoogle Scholar
  22. Rosenthal AK. Calcium crystal deposition and osteoarthritis. Rheum Dis Clin North Am. 2006;32:401–12PubMedCrossRefGoogle Scholar
  23. Schumacher H, Sieck M, Rothfuss S, et al Reproducibility of synovial fluid analyses. Arthritis Rheum. 1986;29:770–4PubMedCrossRefGoogle Scholar
  24. Terkeltaub R. Firestein GS, Budd RC, Harris ED, Jr., Mclnnes IB, Ruddy S, Sergent JS. Diseases associated with articular deposition of calcium pyrophosphate dihydrate and basic calcium phosphate crystals. In: Firestein G et al, editor. Kelley's textbook of rheumatology, 8th ed, WB Saunders, Philadelphia, 2008Google Scholar
  25. Viriyavejkul P, Wilairatana V, Tanavalee A, et al Comparison of characteristics of patients with and without calcium pyrophosphate dihy-drate crystal deposition disease who underwent total knee replacement surgery for osteoarthritis. Osteoarthr Cartil 2006;13: 232–5Google Scholar
  26. Visinoni RA, Ferraz MB, Furlanetto RP, et al Hypothyroidism and chondrocalcinosis: new evidence for lack of association between the 2 pathologies. J Rheumatol. 1993;20:1991–2PubMedGoogle Scholar
  27. Wilkins E, Dieppe P, Maddison P, et al Osteoarthritis and articular chondrocalcinosis in the elderly. Ann Rheum Dis. 1983;42: 280–4PubMedCrossRefGoogle Scholar
  28. Yuan S, Bien C, Wener M, et al Repeat examination of synovial fluid for crystals: Is it useful? Clin Chem. 2003;49:1562–3PubMedCrossRefGoogle Scholar
  29. Zaka R, Williams CJ. Role of the progressive ankylosis gene in cartilage mineralization. Curr Opin Rheumatol. 2006;18:181–6PubMedCrossRefGoogle Scholar
  30. Zhang Y, Johnson K, Russell RG, et al Association of sporadic chondro-calcinosis with a -4-basepair G-to-A transition in the 5′-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum. 2005;52:1110–7PubMedCrossRefGoogle Scholar
  31. Zhang Y, Terkeltaub R, Nevitt M, et al Lower prevalence of chondrocal-cinosis in Chinese subjects in Beijing than in white subjects in the United States: the Beijing Osteoarthritis Study. Arthritis Rheum. 2006;54:3508–12PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Ann K. Rosenthal
    • 1
  • Robert A. Terkeltaub
    • 2
  1. 1.Medical College of Wisconsin Division of Rheumatology
  2. 2.VA Division of RheumatologyVA Healthcare San Diego, University of California, San DiegoSan DiegoUSA

Personalised recommendations